Astrazeneca Pharma India Ltd
₹5957
+6.50 (0.11%)
Thu, 22 Oct 2026, 07:44 pm
Health Technology
Pharmaceuticals: Major
24.5KAstrazeneca Pharma India Ratios
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 29.61 | 30.61 | 26.62 | 16.73 | 41.18 | 60.81 | 262.27 | 0 | 0 | 0 | 550.79 | 117.59 | 89.09 | 91.75 | 82.80 | 80.66 | 103.71 | 81.76 | 82.35 | 185.90 |
| Price to book ratio | 10.03 | 10.52 | 10.27 | 10.63 | 16.42 | 17.36 | 27.40 | 16.39 | 16.08 | 15.21 | 18.53 | 10.55 | 9.38 | 16.61 | 16.41 | 19.61 | 14.55 | 15.72 | 20.80 | 30.82 |
| Price to sales ratio | 5.66 | 5.53 | 5.38 | 3.49 | 5.98 | 6.57 | 9.51 | 4.19 | 5.83 | 4.89 | 5.13 | 4.33 | 4.06 | 6.86 | 7.19 | 9.31 | 7.93 | 8.09 | 10.27 | 12.54 |
| Price to cash flow ratio | 41.19 | 25.14 | 37.56 | 13.51 | 65.23 | 44.69 | 120.68 | 0 | 972.64 | 0 | 46.80 | 53.74 | 138.20 | 75.69 | 60.18 | 65.96 | 57.09 | 99.68 | 221.83 | 221.49 |
| Enterprise value | 1208Cr | 1383Cr | 1525Cr | 1154Cr | 2306Cr | 3044Cr | 5135Cr | 1616Cr | 2671Cr | 2267Cr | 2815Cr | 2236Cr | 2190Cr | 4822Cr | 5738Cr | 7185Cr | 5949Cr | 7625Cr | 12800Cr | 21015Cr |
| Enterprise value to EBITDA ratio | 19.65 | 19.16 | 16.91 | 10.25 | 25.70 | 36.69 | 114.81 | 0 | 0 | 0 | 168.15 | 59.71 | 44.76 | 67.12 | 47.01 | 54.18 | 67.31 | 45.59 | 68.56 | 81.55 |
| Debt to equity ratio | 0 | 0 | 0 | 0.54 | 0.01 | 0.05 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.05 |
| Return on equity % | 38.66 | 36.25 | 40.83 | 53.61 | 44.21 | 31.65 | 10.71 | -61.95 | -0.38 | -12.93 | 3.43 | 10.58 | 12.12 | 19.88 | 21.71 | 24.94 | 14.97 | 20.79 | 27.95 | 17.31 |
Astrazeneca Pharma India Ltd Ratios
The Astrazeneca Pharma India Ltd Ratios page provides a complete fundamental analysis of Astrazeneca Pharma India Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Astrazeneca Pharma India Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Astrazeneca Pharma India Ltd (NSE: ASTRAZEN, BSE: 506820) is currently trading at ₹5957, with a market capitalization of ₹14717.5Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Astrazeneca Pharma India Ltd remains a key stock for fundamental analysis using Astrazeneca Pharma India Ltd Ratios.
Astrazeneca Pharma India Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Astrazeneca Pharma India Ltd P/E ratio currently stands at 185.90, making it one of the most tracked metrics in Astrazeneca Pharma India Ltd Ratios.
Historically, the Astrazeneca Pharma India Ltd P/E ratio has shown strong fluctuations:
- 2025: 185.90
- 2024: 82.35
- 2023: 81.76
- 2022: 103.71
- 2021: 80.66
The rising Astrazeneca Pharma India Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Astrazeneca Pharma India Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 30.82.
Historical P/B trend:
- 2025: 30.82
- 2024: 20.80
- 2023: 15.72
- 2022: 14.55
Astrazeneca Pharma India Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Astrazeneca Pharma India Ltd P/S ratio currently stands at 12.54, an important part of Astrazeneca Pharma India Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2025: 12.54
- 2024: 10.27
- 2023: 8.09
- 2022: 7.93
The rising Astrazeneca Pharma India Ltd P/S ratio indicates improved revenue valuation by investors.
Astrazeneca Pharma India Ltd Price to Cash Flow Ratio (P/CF)
The Astrazeneca Pharma India Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 221.49.
Historical Astrazeneca Pharma India Ltd Price to Cash Flow Ratio:
- 2025: 221.49
- 2024: 221.83
- 2023: 99.68
- 2022: 57.09
- 2021: 65.96
The declining Astrazeneca Pharma India Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Astrazeneca Pharma India Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Astrazeneca Pharma India Ltd EV currently stands at ₹21015Cr, representing the total company valuation including debt.
Historical EV trend:
- 2025: 21015Cr
- 2024: 12800Cr
- 2023: 7625Cr
- 2022: 5949Cr
Astrazeneca Pharma India Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Astrazeneca Pharma India Ltd EV/EBITDA ratio is currently 81.55, a key metric in Astrazeneca Pharma India Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2025: 81.55
- 2024: 68.56
- 2023: 45.59
- 2022: 67.31
Higher Astrazeneca Pharma India Ltd EV/EBITDA suggests premium valuation.
Astrazeneca Pharma India Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Astrazeneca Pharma India Ltd D/E ratio is currently 0.05, reflecting leverage and financial stability.
Historical D/E:
- 2025: 0.05
- 2024: 0.01
- 2023: 0.01
- 2022: 0.02
Astrazeneca Pharma India Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Astrazeneca Pharma India Ltd ROE currently stands at 17.31%, showing profitability and capital efficiency.
Historical ROE:
- 2025: 17.31
- 2024: 27.95
- 2023: 20.79
- 2022: 14.97
Astrazeneca Pharma India Ltd maintains stable profitability levels.
Astrazeneca Pharma India Ltd Ratios Analysis Summary
The Astrazeneca Pharma India Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Astrazeneca Pharma India Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Astrazeneca Pharma India Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
